Condition
Hereditary Spherocytosis
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Terminated1
Withdrawn1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04451785Not ApplicableCompletedPrimary
Hereditary Spherocytosis and Vascular Function
NCT01276561Not ApplicableWithdrawnPrimary
Single Incision Versus Standard Laparoscopic Splenectomy
NCT01141621TerminatedPrimary
The Dallas Hereditary Spherocytosis Cohort Study
Showing all 3 trials